Search results
Order by most recent / most popular / relevance
Results: 1-10 of 196
Definition of “innovative drug” does not include variations
- Borden Ladner Gervais LLP
- -
- Canada
- -
- January 23 2013
This is an appeal by Takeda of a decision of the Court, in which the Court upheld the decision of the Minister of Health to refuse to list Takeda’s
Leave to appeal to the Court of Appeal Re: motion to strike pleadings granted in respect of claims to unjust enrichment, denied in respect of claims under the Trade-Marks Act
- Borden Ladner Gervais LLP
- -
- Canada
- -
- March 6 2013
In this case, Apotex has sued Eli Lilly for damages pursuant to s. 8 of the Patented Medicines (Notice of Compliance) Regulations. Eli Lilly brought a
Eli Lilly Canada Inc. et al. v. Novopharm Limited
- Borden Ladner Gervais LLP
- -
- Canada
- -
- March 15 2010
Lilly commenced an action for patent infringement, and Novopharm, by way of counterclaim, brought an action for damages pursuant to s 8 of the Patented Medicines (Notice of Compliance) Regulations
Canada (Minister of Health) v. Merck Frosst Canada Ltd
- Borden Ladner Gervais LLP
- -
- Canada
- -
- March 15 2010
An English translation of a decision relating to two appeals issued in May 2009 was issued by the Court
Apotex Inc. v. Merck Frosst Canada & Co.
- Borden Ladner Gervais LLP
- -
- Canada
- -
- March 15 2010
This is an action decided under s 8 of the Patented Medicines (Notice of Compliance) Regulations between Apotex and Merck relating to norfloxacin
Sanofi-aventis Canada Inc. et al. v. Novopharm Limited
- Borden Ladner Gervais LLP
- -
- Canada
- -
- March 15 2010
Following an infringement trial, where the patent was found to be invalid, Novopharm’s counterclaim under s 8 of the Patented Medicines (Notice of Compliance) Regulations is going forward
Apotex Inc. v. sanofi-aventis
- Borden Ladner Gervais LLP
- -
- Canada
- -
- March 15 2010
Apotex commenced an impeachment action against sanofi-aventis
Other industry happenings of note
- Borden Ladner Gervais LLP
- -
- Canada
- -
- March 15 2010
Health Canada published a Guidance for Sponsors: Information and Submission Requirements for Subsequent Entry Biologics (SEBs) and updated the Guidance Documents for Data Protection and the PMNOC Regulations
sanofi v. Pharmascience
- Borden Ladner Gervais LLP
- -
- Canada
- -
- May 25 2010
This is an assessment of costs following the discontinuance of a proceeding under the Patented Medicines (Notice of Compliance) Regulations
Eli Lilly Canada v Novopharm
- Borden Ladner Gervais LLP
- -
- Canada
- -
- June 2 2010
For the purposes of an appeal being heard shortly, Lilly filed a compendium containing the documents referred to in its Memorandum of Fact and Law, as well as 13 additional volumes containing documents from the appeal book and an additional Book of Authorities
Current Search
- Workarea - Healthcare
- Author - Chantal Saunders
- Jurisdiction - Canada